THE CDMO Rentschler Biopharma has announced that Patrick Cushing, Ph.D., has been appointed Vice President Operations of Rentschler Biopharma, Inc., the company's U.S. subsidiary, effective 1 May. In this newly created position, Dr Cushing will oversee and manage all operations at the site, reporting to Rentschler Biopharma's Chief Operating Officer, Christiane Bardroff. From a US perspective, he will report to Tom Roberts, President and General Manager of Rentschler Biopharma, Inc.
Christiane Bardroff, Chief Operating Officer of Rentschler Biopharma, stated: "The appointment of Patrick Cushing to Vice President Operations at our state-of-the-art manufacturing site in Milford reflects our commitment to delivering the highest quality services to our clients. His unwavering dedication aligns perfectly with our vision of advancing medicine to save lives. The creation of this new position recognizes many important milestones we have achieved during the last months, with new manufacturing lines coming online at our U.S. facility. Patrick brings exceptional leadership skills to this role, having consistently demonstrated his ability to work not only with his team and across departments but also with colleagues from other Rentschler Biopharma sites to develop and manufacture a broad range of innovative therapies. In his new role, he will serve to further streamline and strengthen the organization as we support existing and new clients in the U.S.”
Patrick Cushing, Vice President Operations of the Contract Development and Manufacturing Organisation, emphasises:: “I am excited to take on this new role as we significantly expand our capacity in the U.S. At Rentschler Biopharma, we are truly one team. In my new role, I am particularly looking forward to leveraging synergies with our global organization to further streamline the development and increase the agility with which we bring new medicines to market. I am confident in our team's ability to make a positive difference in the lives of patients worldwide, and I am honored to be part of this impactful journey.”
Cushing joined Rentschler Biopharma in 2021 as Senior Director of Manufacturing Operations at the company's Milford, MA site, demonstrating exceptional biopharmaceutical management skills cultivated through leadership roles in contract research and contract manufacturing organisations. With over a decade of experience in structure-based drug discovery and large molecule process development, he has been instrumental in improving chemistry, manufacturing and controls (CMC) processes. His expertise spans the development of diverse molecules from plasmid DNA to recombinant proteins, including complex biologics such as challenging proteins, bispecific antibodies, enzymes and protein complexes. Patrick's commitment to excellence ensures the seamless translation of novel therapeutics from the laboratory to production and continues to shape the future of biopharmaceutical manufacturing.
The new manufacturing line at the Milford site provides 22,000 square feet of manufacturing cleanroom space and houses four new 2,000 L single-use bioreactors. This is the largest expansion in the company's more than 150-year history and will double Rentschler Biopharma's global cGMP capacity. Customers benefit from the company's global integrated service offering and proven expertise in bioprocess development and manufacturing along the entire biopharmaceutical value chain. The facility will focus on the commercial production of highly complex molecules for international customers. In December 2023, the company announced that it had secured a major customer for the new production line.
